PALI Stock Analysis: Buy, Sell, or Hold?
PALI - Palisade Bio, Inc. Common Stock
$2.10
0.13 (6.60%)
▲
5d:
+16.67%
30d:
+12.9%
90d:
+11.7%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When PALI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PALI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PALI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PALI is currently trading at $2.10, which is considered extended relative to its 30-day fair value range of $1.75 to $2.05.
Technical Outlook: Technically, PALI is in a uptrend. The price is approaching resistance at $2.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: PALI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.50 (+400.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PALI is in a uptrend. The price is approaching resistance at $2.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: PALI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.50 (+400.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.75 -
$2.05
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 400.0% below Wall St target ($10.50)
Trading Range Analysis
30-Day Trading Range
$1.75 -
$2.05
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.64
Resistance Level
$2.16
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.35
Wall Street Target
$10.50
(+400.0%)
Share & Embed Analysis
Last updated: July 03, 2026 6:20 PM ET
Data refreshes hourly during market hours. Next update: 7:20 PM
Data refreshes hourly during market hours. Next update: 7:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PALI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
John David Finley
SELL
3896 shares
2026-02-12
Mitchell Lawrence Jones
SELL
1989 shares
2026-02-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
